Don’t Delay With Delta: Live Questions on Best Practices for HDV Screening and Management

In this live, 45-minute Webinar, have your questions about screening, diagnosis, and management of hepatitis delta virus (HDV) answered by expert faculty.


  • Attendee questions answered by the faculty experts on hepatitis delta virus (HDV)
    • Are you practicing risk-based or universal screening for HDV?
    • Should you perform HDV RNA reflex testing following a positive hepatitis delta antibody test?
    • How are you linking into care your patients newly diagnosed with HDV?
    • Are you properly counseling your patients with HDV on their liver disease and liver cancer risks?
    • What are current and evolving treatment options for HDV?


Maria Buti, MD

Professor of Medicine
Hospital Universitario Vall d'Hebron
Barcelona, Spain

Robert G. Gish, MD

Professor of Medicine
Loma Linda University
Loma Linda, California
Adjunct Professor of Medicine
Nevada School of Medicine
Las Vega, Nevada
Clinical Professor
University of Nevada Reno School of Medicine
Clinical Professor
University of California Skaggs School of Pharmacy and Pharmaceutical Sciences
San Diego, California
Medical Director

Hepatitis B Foundation
Washington, DC

This educational activity is not certified for CME/CE credit.

Goal Statement
The goal of this program is to improve healthcare professionals’ (HCPs) awareness of HDV and the importance of screening in patients with HBV, as well as their competence in treating patients living with hepatitis B virus (HBV)/HDV coinfection.

Target Audience
This program is intended for physicians, registered nurses, nurse practitioners, physician assistants, and other HCPs who provide care for patients with HDV infection.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Implement screening practices that ensure that patients at risk for HDV infection are promptly diagnosed and appropriately counseled
  • Apply optimal treatment strategies for patients with chronic HDV infection
  • Recount key safety and efficacy data from clinical trials of investigational agents for chronic HDV


This educational activity is not certified for CME/CE credit.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.